| Abstrakt: |
The review discusses experimental and clinical data from recent decades on the use of geroprotective agents of the mTOR inhibitor group for the main and accompanying treatment of cancer patients. The mTOR protein kinase is an interesting therapeutic target for the treatment of multiple cancers with both mTOR inhibitors themselves (rapamycin and its derivatives) and in combination with inhibitors of other pathways (e.g., metformin). mTOR inhibitors, which are not classical cytostatic agents and do not possess carcinogenic activity, show great promise as independent antitumor agents and in combination with conventional chemotherapy. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink